BACKGROUND: Varicella-zoster virus (VZV)-specific cell-mediated immunity is important for protection against VZV disease. We studied the relationship between VZV cell-mediated immunity and age after varicella or VZV vaccination in healthy and human immunodeficiency virus (HIV)-infected individuals. METHODS: VZV responder cell frequency (RCF) determinations from 752 healthy and 200 HIV-infected subjects were used to identify group-specific regression curves on age. RESULTS: In healthy individuals with past varicella, VZV RCF peaked at 34 years of age. Similarly, VZV-RCF after varicella vaccine increased with age in subjects aged <1 to 43 years. In subjects aged 61-90 years, VZV RCF after zoster vaccine decreased with age. HIV-infected children had lower VZV RCF estimates than HIV-infected adults. In both groups, VZV RCF results were low and constant over age. Varicella vaccination of HIV-infected children with CD4 levels 20% generated VZV RCF values higher than wild-type infection and comparable to vaccine-induced responses of healthy children. CONCLUSIONS: In immunocompetent individuals with prior varicella, VZV RCF peaked in early adulthood. Administration of varicella vaccine to HIV-infected or uninfected individuals aged >5 years generated VZV RCF values similar to those of immunocompetent individuals with immunity induced by wild-type infection. A zoster vaccine increased the VZV RCF of elderly adults aged <75 years to values higher than peak values induced by wild-type infection.
BACKGROUND:Varicella-zoster virus (VZV)-specific cell-mediated immunity is important for protection against VZV disease. We studied the relationship between VZV cell-mediated immunity and age after varicella or VZV vaccination in healthy and humanimmunodeficiency virus (HIV)-infected individuals. METHODS:VZV responder cell frequency (RCF) determinations from 752 healthy and 200 HIV-infected subjects were used to identify group-specific regression curves on age. RESULTS: In healthy individuals with past varicella, VZV RCF peaked at 34 years of age. Similarly, VZV-RCF after varicella vaccine increased with age in subjects aged <1 to 43 years. In subjects aged 61-90 years, VZV RCF after zoster vaccine decreased with age. HIV-infectedchildren had lower VZV RCF estimates than HIV-infected adults. In both groups, VZV RCF results were low and constant over age. Varicella vaccination of HIV-infectedchildren with CD4 levels 20% generated VZV RCF values higher than wild-type infection and comparable to vaccine-induced responses of healthy children. CONCLUSIONS: In immunocompetent individuals with prior varicella, VZV RCF peaked in early adulthood. Administration of varicella vaccine to HIV-infected or uninfected individuals aged >5 years generated VZV RCF values similar to those of immunocompetent individuals with immunity induced by wild-type infection. A zoster vaccine increased the VZV RCF of elderly adults aged <75 years to values higher than peak values induced by wild-type infection.
Authors: Shu Li; Ivan S F Chan; Holly Matthews; Joseph F Heyse; Christina Y Chan; Barbara J Kuter; Karen M Kaplan; S J Rupert Vessey; Jerald C Sadoff Journal: Pediatr Infect Dis J Date: 2002-04 Impact factor: 2.129
Authors: Barbara Kuter; Holly Matthews; Henry Shinefield; Steve Black; Penelope Dennehy; Barbara Watson; Keith Reisinger; Lee Lian Kim; Lisa Lupinacci; Jonathan Hartzel; Ivan Chan Journal: Pediatr Infect Dis J Date: 2004-02 Impact factor: 2.129
Authors: Christiane S Eberhardt; Andreas Wieland; Tahseen H Nasti; Alba Grifoni; Elizabeth Wilson; D Scott Schmid; Bali Pulendran; Alessandro Sette; Edmund K Waller; Nadine Rouphael; Rafi Ahmed Journal: J Virol Date: 2020-06-16 Impact factor: 5.103
Authors: Benson Ogunjimi; Evelien Smits; Steven Heynderickx; Johan Van den Bergh; Joke Bilcke; Hilde Jansens; Ronald Malfait; Jose Ramet; Holden T Maecker; Nathalie Cools; Philippe Beutels; Pierre Van Damme Journal: Clin Vaccine Immunol Date: 2014-01-15